Mirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024. In the quarter to June 2026, revenue grew 37.9%, EPS fell 783.3%, free cash flow fell 681.5% and total debt rose 142.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow MIRM
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more quarters Free account |
2.91 | (5.73) | (790.15) | (67.23) |
Depreciation & Amortization |
6.51 | 6.51 | 7.33 | 7.59 | |
Non Cash Items (Other) |
18.13 | 19.29 | 451.85 | 55.60 | |
Accounts Receivable Change |
(3.15) | (19.01) | (12.89) | (13.74) | |
Change in inventories |
(1.16) | (2.28) | (1.92) | 0.40 | |
Change in payables and accrued liability |
24.35 | 3.44 | 57.24 | (19.06) | |
Change in other assets and liabilities |
(7.90) | 3.84 | 59.78 | (7.81) | |
Operating Cash Flow |
39.68 | 6.07 | (228.76) | (44.25) | |
Capital expenditures |
(0.19) | (0.60) | (0.66) | (0.02) | |
Change in intangibles (net) |
— | — | (10.00) | (25.00) | |
Short Term Investments Change (Net) |
(2.04) | 1.61 | (0.90) | (134.97) | |
Investing cash flow |
(2.23) | 1.01 | (11.57) | (159.99) | |
Repayment/Issuance of Debt (Net) |
— | — | — | 198.07 | |
Equity Repurchase (Common, Net) |
16.10 | 9.00 | 270.08 | 13.37 | |
Financing cash flow |
16.10 | 9.00 | 270.08 | 211.44 | |
Exchange Rate Adjustment |
0.35 | (0.41) | (1.27) | (1.37) | |
Change in Cash |
53.90 | 15.66 | 28.48 | 5.82 | |
Beginning Cash |
0.00 | 0.00 | 298.17 | 0.00 | |
Ending Cash |
53.90 | 15.66 | 326.64 | 5.82 | |
Stock Based Compensation |
18.13 | 19.03 | 36.20 | 30.57 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
12.15 | (14.01) | 102.22 | (40.22) | |
Investments Change (Net) |
(2.04) | 1.61 | (0.90) | (134.97) | |
Issuance/Purchase of Shares |
16.10 | 9.00 | 270.08 | 13.37 |